BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 32296025)

  • 1. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.
    Lin X; Li AM; Li YH; Luo RC; Zou YJ; Liu YY; Liu C; Xie YY; Zuo S; Liu Z; Liu Z; Fang WY
    Signal Transduct Target Ther; 2020 Feb; 5(1):13. PubMed ID: 32296025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
    Lin X; Zuo S; Luo R; Li Y; Yu G; Zou Y; Zhou Y; Liu Z; Liu Y; Hu Y; Xie Y; Fang W; Liu Z
    Theranostics; 2019; 9(25):7583-7598. PubMed ID: 31695788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-C-(E-Phenylethenyl)Naringenin Attenuates the Stemness of Hepatocellular Carcinoma Cells by Suppressing Wnt/β-Catenin Signaling.
    Kang Q; Gong J; Wang M; Wang Q; Chen F; Cheng KW
    J Agric Food Chem; 2019 Dec; 67(50):13939-13947. PubMed ID: 31769973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBx mutations promote hepatoma cell migration through the Wnt/β-catenin signaling pathway.
    Chen Z; Tang J; Cai X; Huang Y; Gao Q; Liang L; Tian L; Yang Y; Zheng Y; Hu Y; Tang N
    Cancer Sci; 2016 Oct; 107(10):1380-1389. PubMed ID: 27420729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
    Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
    Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
    Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
    Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus X protein promotes the stem-like properties of OV6
    Wang C; Wang MD; Cheng P; Huang H; Dong W; Zhang WW; Li PP; Lin C; Pan ZY; Wu MC; Zhou WP
    Cell Death Dis; 2017 Jan; 8(1):e2560. PubMed ID: 28102846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway.
    Xie Q; Chen L; Shan X; Shan X; Tang J; Zhou F; Chen Q; Quan H; Nie D; Zhang W; Huang AL; Tang N
    Int J Cancer; 2014 Aug; 135(3):635-46. PubMed ID: 24374650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis.
    Hou R; Li Y; Luo X; Zhang W; Yang H; Zhang Y; Liu J; Liu S; Han S; Liu C; Huang Y; Liu Z; Li A; Fang W
    Int J Biol Sci; 2022; 18(6):2553-2567. PubMed ID: 35414777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
    Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
    Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.
    Yu Z; Feng H; Zhuo Y; Li M; Zhu X; Huang L; Zhang X; Zhou Z; Zheng C; Jiang Y; Le F; Yu DY; Cheng AS; Sun X; Gao Y
    Cell Oncol (Dordr); 2020 Dec; 43(6):1129-1145. PubMed ID: 32623699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis.
    Chen SL; Liu LL; Lu SX; Luo RZ; Wang CH; Wang H; Cai SH; Yang X; Xie D; Zhang CZ; Yun JP
    Mol Oncol; 2017 Sep; 11(9):1225-1240. PubMed ID: 28580773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
    Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
    Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
    Deng X; Zhao XF; Liang XQ; Chen R; Pan YF; Liang J
    Biomed Pharmacother; 2017 Jun; 90():100-108. PubMed ID: 28343069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T; Zhu X; Zhu K; Jia F; Li S
    Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.